Navigation Links
Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
Date:9/6/2011

SAN DIEGO, Sept. 6, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) is updating the date and time of the Company's presentation at the Stifel Nicolaus Healthcare Conference to Thursday, September 8, 2011 at 4:25 p.m. EDT (1:25 p.m. PDT).  The conference is being held at the Four Seasons Hotel in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, setrobuvir and ANA773.

The presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through September 22, 2011.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C.  The Company is  also developing ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C and plans to initiate a Phase IIa study shortly.

Safe Harbor Statement

Statements in this press release that are not strictly historica
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... Using microscopic polymer light resonators that expand in ... Quantum Photonics Laboratory have developed new optical sensors ... Optical sensors are ideal for detecting trace gas ... lightweight nature, and immunity to electromagnetic interference. , ... before, the MIT team conceived an extremely sensitive, ...
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2
... AMDL, Inc. (Amex:,ADL), with operations in Shenzhen, ... subsidiary Jade Pharmaceutical Inc. (JPI), an international,biopharma ... and,marketing of proprietary pharmaceutical and diagnostic products, ... expansion plans to increase,annualized sales in FY2008, ...
... Nov. 20 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of,Sangamo,s ZFP Therapeutic ... at 11:00 am (ET) on Wednesday, November 28,2007 at ... New York. The presentation will be webcast live ...
... FOLD ) today announced that John F. Crowley, ... at the Lazard Capital,Markets Fourth Annual Healthcare Conference in ... ET at The New York Palace Hotel. A ... available to all,interested parties through the Investors section of ...
Cached Biology Technology:AMDL Launches New JPGreen Business Strategy 2Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... at Mount Sinai School of Medicine have discovered a ... and resistance to chemotherapy, and participate in tumor progression. ... tests for early cancer diagnosis, prognostic tests, and innovative ... Resistance to chemotherapy is a frequent ...
... The decision has been taken by the German government to ... The transition process is gaining impetus but much remains to ... wind energy is to be dramatically expanded not only ... still immense potential inland that remains to be tapped, such ...
... appreciate this fabric, which looks innocuous but in fact ... a microcontroller that detects warning signals emitted when the ... can be used to protect buildings, bank vaults, and ... parked overnight at truck stops are particularly vulnerable to ...
Cached Biology News:Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel' 2More accurate wind energy forecasts 2More accurate wind energy forecasts 3A smart fabric sets off the alarm 2A smart fabric sets off the alarm 3
...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: